Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Jiangsu Lianhuan Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:600513'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -13.9 Med: 8.9 Max: 13.23
Current: -13.9
During the past 13 years, Jiangsu Lianhuan Pharmaceutical Co's highest Return-on-Tangible-Equity was 13.23%. The lowest was -13.90%. And the median was 8.90%.
SHSE:600513's Return-on-Tangible-Equity is ranked worse than 82.76% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.95
vs SHSE:600513: -13.90
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Jiangsu Lianhuan Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Jiangsu Lianhuan Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Lianhuan Pharmaceutical Co Return-on-Tangible-Equity Chart
SHSE:600513 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Lianhuan Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Lianhuan Pharmaceutical Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Lianhuan Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Jiangsu Lianhuan Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 3.56% mean?
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) has a Return-on-Tangible-Equity of 3.56% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. This is 60% below median its historical median of 8.90. According to the industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #744 out of 899 companies in the Drug Manufacturers industry, placing it in the top 82.8%.
Is Jiangsu Lianhuan Pharmaceutical Co's Return-on-Tangible-Equity too high?
Jiangsu Lianhuan Pharmaceutical Co's current Return-on-Tangible-Equity of 3.56% is 60% below median its 10-year median of 8.90. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.95. Jiangsu Lianhuan Pharmaceutical Co's value of 3.56% is 55.2% below this industry median. Based on the distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #744 out of 899 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Lianhuan Pharmaceutical Co has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Lianhuan Pharmaceutical Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #744 out of 899 companies for Return-on-Tangible-Equity. This places Jiangsu Lianhuan Pharmaceutical Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.95. Jiangsu Lianhuan Pharmaceutical Co's value of 3.56% is 55.2% below this benchmark. While the company's 10-year median is 8.90 vs. the industry median of 7.95, Jiangsu Lianhuan Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.95, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Lianhuan Pharmaceutical Co's current Return-on-Tangible-Equity of 3.56% is 55.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Lianhuan Pharmaceutical Co's current Return-on-Tangible-Equity is 3.56%, which is 60% below median its own 10-year median of 8.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Lianhuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥13.72, compared to a current price of ¥15.42 — trading 12.4% above its estimated fair value. The current Return-on-Tangible-Equity is 3.56%, which is 60% below median its 10-year median of 8.90 and 55.2% below the Drug Manufacturers industry median of 7.95. Jiangsu Lianhuan Pharmaceutical Co's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513), the current Return-on-Tangible-Equity is 3.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥15.42 is trading 12.4% above its estimated GF Value™ of ¥13.72.
GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:600513:
Return-on-Tangible-Equity: 3.56% (60% below median its 10-year median of 8.90)
GF Value™: ¥13.72 vs. price of ¥15.42 (12.4% above fair value)
Industry Position: 55.2% below the Drug Manufacturers median (#744 of 899)
No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Lianhuan Pharmaceutical Co Business Description
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
65GF Score
Get the complete analysis for SHSE:600513
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600513 has been successfully added to your 
